UNITED STATES DISTRICT COURT

EASTERN DISTRICT OF CALIFORNIA

FEDERAL TRADE COMMISSION, Plaintiff, vs. **GOLDEN SUNRISE NUTRACEUTICAL, INC.**, *et al*., Defendants.	Case No.: 1:20-cv-01060-DJC-SKO **ORDER FOR PERMANENT INJUNCTION**

Plaintiff, the Federal Trade Commission ("Commission" or "FTC"), filed its Complaint For Permanent Injunction and Other Equitable Relief ("Complaint"), pursuant to Section 13(b) of the Federal Trade Commission Act ("FTC Act"), 15 U.S.C. § 53(b), (ECF No. 2.) Plaintiff moved for summary judgment pursuant to Federal Rule of Civil Procedure 56 on all counts against Defendants Golden Sunrise Nutraceutical, Inc., Golden Sunrise Pharmaceutical, Inc., and Huu Tieu ("Defendants"). Having considered the pleadings in the record, briefs, declarations, and exhibits, the Court has granted Plaintiff's Motion for Summary Judgment, (ECF Nos. 65, 157), and HEREBY ORDERS, ADJUDGES, AND DECREES as follows:

FINDINGS

1. This Court has jurisdiction over this matter.

2. The Complaint charges that Defendants participated in deceptive acts or practices in violation of Sections 5(a) and 12 of the FTC Act, 15 U.S.C. §§ 45(a) and 52, in connection with the labeling, advertising, marketing, distribution, and sale of products they claim will treat, prevent, or cure COVID-19, cancer, and Parkinson's disease.

3. The FTC has established that it is entitled to judgment as a matter of law on all counts for all the reasons stated in this Court's Order granting summary judgment. (ECF. No. 157).

DEFINITIONS

For purposes of this Order, the following definitions apply:

A. "**Covered Product**" means any Dietary Supplement, Food, or Drug, including the products Defendants have marketed as ImunStem, Aktiffvate, AnterFerron-1, AnterFerron-2, CrProtein, DetoxHerb-1, DetoxHerb-2, DetoxHerb-NR, DetoxHerb-PI, KemoHerb-1, KemoHerb-2, KemoHerb-NR, KemoHerb-PI, HyProtein-1, HyProtein-2, HyProtein-3, HyProtein-4, and LyProtein.

B. "**Defendants**" means all of the Corporate Defendants and Individual Defendants, individually, collectively, or in any combination.

1. "**Corporate Defendants**" means Golden Sunrise Nutraceutical, Inc. and Golden Sunrise Pharmaceutical, Inc., and their successors and assigns.

2. "**Individual Defendants**" means Huu Tieu and Stephen Meis.

C. "**Dietary Supplement**" means: (1) any product labeled as a dietary supplement or otherwise represented as a dietary supplement; or (2) any pill, tablet, capsule, powder, softgel, gelcap, liquid, or other similar form containing one or more ingredients that are a vitamin, mineral, herb or other botanical, amino acid, probiotic, or other dietary substance for use by humans to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any ingredient described above, that is intended to be ingested, and is not represented to be used as a conventional food or as a sole item of a meal or the diet.

D. "**Drug**" means: (1) articles recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; (2) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or other animals; (3) articles (other than Food) intended to affect the structure or any function of the body of humans or other animals; and (4) articles intended for use as a component of any article specified in (1), (2), or (3); but does not include devices or their components, parts, or accessories.

E. "**Essentially Equivalent Product**" means a product that contains the identical ingredients, except for inactive ingredients (e.g., inactive binders, colors, fillers, excipients), in the same form and dosage, and with the same route of administration (*e.g.*, orally, sublingually), as the Covered Product; provided that the Covered Product may contain additional ingredients if reliable scientific evidence generally accepted by experts in the field indicates that the amount and combination of additional ingredients are unlikely to impede or inhibit the effectiveness of the ingredients in the Essentially Equivalent Product.

F. "**FDA**" means the United States Food and Drug Administration.

G. "**Food**" means: (1) any article used for food or drink for humans or other animals; (2) chewing gum; and (3) any article used for components of any such article.

ORDER

I. PROHIBITED REPRESENTATIONS REGARDING HEALTH-RELATED CLAIMS REQUIRING HUMAN CLINICAL TESTING FOR SUBSTANTIATION

IT IS ORDERED that Defendants and their officers, agents, employees, and attorneys, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the manufacturing,

labeling, advertising, promotion, offering for sale, or sale of any Covered Product are permanently restrained and enjoined from making, or assisting others in making, expressly or by implication, any representation that such product:

(1) treats, mitigates the symptoms of, or cures COVID-19;

(2) treats, mitigates the symptoms of, or cures cancer;

(3) treats, mitigates the symptoms of, or cures Parkinson's disease; or

(4) prevents, treats, mitigates the symptoms of, or cures any disease, unless the representation is non-misleading, and, at the time of making such representation, they possess and rely upon competent and reliable scientific evidence substantiating that the representation is true.

For purposes of this Section, "competent and reliable scientific evidence" must consist of human clinical testing of the Covered Product, or of an Essentially Equivalent Product, that is sufficient in quality and quantity, based on standards generally accepted by experts in the relevant disease, condition, or function to which the representation relates, when considered in light of the entire body of relevant and reliable scientific evidence, to substantiate that the representation is true. Such testing must be: (1) randomized, double-blind, and placebo-controlled; and (2) conducted by researchers qualified by training and experience to conduct such testing. In addition, all underlying or supporting data and documents generally accepted by experts in the field as relevant to an assessment of such testing as described in the Section titled "Preservation of Records Relating to Competent and Reliable Human Clinical Tests or Studies" must be available for inspection and production to the Commission. Persons covered by this Section have the burden of proving that a product satisfies the definition of an Essentially Equivalent Product.

II. PROHIBITED REPRESENTATIONS: OTHER HEALTH-RELATED CLAIMS

IT IS FURTHER ORDERED that Defendants and their officers, agents, employees, and attorneys, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, or sale of any Covered Product are permanently restrained and enjoined from making, or assisting others in making, expressly or by implication, any representation other than representations covered under the Section of this Order entitled "Prohibited Representations Regarding Health-Related Claims Requiring Human Clinical Testing For Substantiation" about the health benefits, performance, efficacy, safety, or side effects of any Covered Product, unless the representation is non-misleading, and, at the time of making such representation, they possess and rely upon competent and reliable scientific evidence that is sufficient in quality and quantity based on standards generally accepted by experts in the disease, condition, or function to which the representation relates, when considered in light of the entire body of relevant and reliable scientific evidence, to substantiate that the representation is true.

For purposes of this Section, "competent and reliable scientific evidence" means tests, analyses, research, or studies (1) that have been conducted and evaluated in an objective manner by experts in the relevant disease, condition, or function to which the representation relates; (2) that are generally accepted by such experts to yield accurate and reliable results; and (3) that are randomized, double-blind, and placebo-controlled human clinical testing of the Covered Product, or of an Essentially Equivalent Product, when such experts would generally require such human clinical testing to substantiate that the representation is true. In addition, when such tests or studies are human clinical tests or studies, all underlying or supporting data and documents

generally accepted by experts in the field as relevant to an assessment of such testing as set forth in the Section entitled "Preservation of Records Relating to Competent and Reliable Human Clinical Tests or Studies" must be available for inspection and production to the Commission. Persons covered by this Section have the burden of proving that a product satisfies the definition of an Essentially Equivalent Product.

III. PRESERVATION OF RECORDS RELATING TO COMPETENT AND RELIABLE HUMAN CLINICAL TESTS OR STUDIES

IT IS FURTHER ORDERED that, with regard to any human clinical test or study ("Test") upon which Defendants rely to substantiate any claim covered by this Order, Defendants must secure and preserve all underlying or supporting data and documents generally accepted by experts in the field as relevant to an assessment of the Test, including:

A. All protocols and protocol amendments, reports, articles, write-ups, or other accounts of the results of the Test, and drafts of such documents reviewed by the Test sponsor or any other person not employed by the research entity;

B. All documents referring or relating to recruitment; randomization; instructions, including oral instructions, to participants; and participant compliance;

C. Documents sufficient to identify all Test participants, including any participants who did not complete the Test, and all communications with any participants relating to the Test; all raw data collected from participants enrolled in the Test, including any participants who did not complete the Test; source documents for such data; any data dictionaries; and any case report forms;

D. All documents referring or relating to any statistical analysis of any Test data, including any pretest analysis, intent-to-treat analysis, or between-group analysis performed on any Test data; and

E. All documents referring or relating to the sponsorship of the Test, including all communications and contracts between any sponsor and the Test's researchers.

Provided, however, the preceding preservation requirement does not apply to a Reliably Reported Test, unless the Test was conducted, controlled, or sponsored, in whole or in part by: (1) any Defendant; (2) any Defendant's officers, agents, representatives, or employees; (3) any other person or entity in active concert or participation with any Defendant; (4) any person or entity affiliated with or acting on behalf of any Defendant; (5) any supplier of any ingredient contained in the product at issue to any of the foregoing or to the product's manufacturer; or (6) the supplier or manufacturer of such product.

For purposes of this Section, "Reliably Reported Test" means a report of the Test has been published in a peer-reviewed journal, and such published report provides sufficient information about the Test for experts in the relevant field to assess the reliability of the results.

For any Test conducted, controlled, or sponsored, in whole or in part, by Defendants, Defendants must establish and maintain reasonable procedures to protect the confidentiality, security, and integrity of any personal information collected from or about participants. These procedures must be documented in writing and must contain administrative, technical, and physical safeguards appropriate to the size, complexity, nature, and scope of Defendants' activities, and the sensitivity of the personal information collected from or about the participants.

IV. PROHIBITED MISREPRESENTATIONS REGARDING TESTS, STUDIES, OTHER RESEARCH, OR FDA APPROVAL

IT IS FURTHER ORDERED that Defendants and their officers, agents, employees, and attorneys, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly, in connection with the manufacturing, labeling, advertising, promotion, offering for sale, or sale of any product are permanently restrained and enjoined from misrepresenting, in any manner, expressly or by implication:

A. That any Covered Product is:

(i) clinically proven to treat, mitigate the symptoms of, or cure COVID-19;

(ii) clinically proven to treat, mitigate the symptoms of, or cure cancer;

(iii) clinically proven to treat, mitigate the symptoms of, or cure Parkinson's disease;

(iv) clinically proven to prevent, treat, mitigate the symptoms of, or cure any disease or condition;

(v) accepted, approved, authorized, endorsed, or proven effective by the FDA; or

(vi) accepted, approved, authorized, or registered by the FDA as a Dietary Supplement, Drug, or Regenerative Medicine Advance Therapy;

B. That the performance or benefits of any product are scientifically or clinically proven or otherwise established; or

C. The existence, contents, validity, results, conclusions, or interpretations of any Test, study, or other research.

V. FDA APPROVED CLAIMS

IT IS FURTHER ORDERED that nothing in this Order prohibits Defendants or their officers, agents, employees, and attorneys, or all other persons in active concert or participation

with any of them, from:

A. For any Drug, making a representation that is approved in labeling for such Drug under any tentative final or final monograph promulgated by the FDA, or under any new Drug application approved by the FDA; and

B. For any product, making a representation that is specifically authorized in labeling for such product by regulations promulgated by the FDA pursuant to the Nutrition Labeling and Education Act of 1990 or authorized under Sections 303-304 of the Food and Drug Administration Modernization Act of 1997.

VI. CERTAIN CONSUMER DEBTS EXTINGUISHED

IT IS FURTHER ORDERED that Defendants and their officers, agents, employees, and attorneys, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, whether acting directly or indirectly:

A. Are permanently restrained and enjoined from:

1. Collecting upon or making any attempt to collect upon any debt arising from the sale of a Covered Product;
2. Selling, assigning, or otherwise transferring, any debt arising from the sale of a Covered Product; and
3. Furnishing or reporting any debt arising from the sale of a Covered Product to any consumer reporting agency.

B. Defendants shall, within 10 business days of entry of this Order, request that any consumer reporting agency that Defendants furnished with information relating to any debt arising from the sale of a Covered Product delete and extinguish the debt from the consumer's

credit reporting file.

VII. NOTICE TO CUSTOMERS

IT IS FURTHER ORDERED that Defendants:

A. Identify all consumers who were prescribed or sold a Covered Product on or after December 2016 ("Eligible Customers"):

1. Such Eligible Customers, and their contact information, must be identified to the extent such information is in Defendants' possession, custody, or control, including from third parties.
2. Eligible Customers include those identified at any time up to one year after the issuance of this Order.

B. Send each Eligible Customer a notice via electronic mail or, if electronic mailing information is not available, by physical mail:

1. The notice must be in the form shown in **Attachment A**.
2. The envelope containing any notice sent by physical mail must be in the form shown in **Attachment B**.
3. The subject line of the notice must state, "About Your Treatment with Golden Sunrise Products."
4. The notice must not include any other attachments.

C. Notify all Eligible Customers within 45 days after the issuance date of this Order and any Eligible Customers identified thereafter within 30 days of their identification.

D. Report on their notification program under penalty of perjury:

1. Defendants must submit a report within 90 days after the issuance date of this Order summarizing their compliance to date, including the total number of Eligible Customers identified and notified.
2. If a representative of the Commission requests any information regarding the program, including any of the underlying customer data, he must submit it within 10 days of the request.
3. Failure to provide required notices or any requested information will be treated as a continuing failure to obey this Order.

VIII. NOTICE TO RESELLERS

IT IS FURTHER ORDERED that within 30 days of the effective date of this Order, Defendants must notify all retailers or resellers by sending each by first-class mail, postage paid and return receipt requested, or by courier service with signature proof of delivery, the notification letter attached as **Attachment C**. Defendants must include a copy of this Order, but no other document or enclosure.

IX. CUSTOMER INFORMATION

IT IS FURTHER ORDERED that Defendants and their officers, agents, employees, and attorneys, and all other persons in active concert or participation with any of them, who receive actual notice of this Order, are permanently restrained and enjoined from directly or indirectly:

A. Failing to provide sufficient customer information to enable the Commission to efficiently administer consumer redress. Defendants represent that he has provided this redress information to the Commission. If a representative of the Commission requests in writing any

information related to redress, Defendants must provide it, in the form prescribed by the Commission, within 14 days.

B. Disclosing, using, or benefitting from customer information, including the name, address, telephone number, email address, social security number, sensitive health information, other identifying information, or any data that enables access to a customer's account (including a credit card, bank account, or other financial account), that any Defendant obtained prior to entry of this Order in connection with the labeling, advertising, marketing, distribution, and sale of products they claim will treat, prevent, or cure COVID-19, cancer, and Parkinson's disease.

C. Failing to destroy such customer information in all forms in their possession, custody, or control within 30 days after receipt of written direction to do so from a representative of the Commission.

Provided, however, that customer information need not be disposed of, and may be disclosed, to the extent requested by a government agency or required by law, regulation, or court order.

X. COOPERATION

IT IS FURTHER ORDERED that each of the Defendants must fully cooperate with representatives of the Commission in this case and in any investigation related to or associated with the transactions or the occurrences that are the subject of the Complaint. Defendants must provide truthful and complete information, evidence, and testimony. Defendant Huu Tieu must appear and Corporate Defendants must cause Corporate Defendants' officers, employees, representatives, or agents to appear for interviews, discovery, hearings, trials, and any other proceedings that a Commission representative may reasonably request upon 10 days written

notice, or other reasonable notice, at such places and times as a Commission representative may designate, without the service of a subpoena.

XI. ORDER ACKNOWLEDGMENTS

IT IS FURTHER ORDERED that Defendants obtain acknowledgments of receipt of this Order:

A. Each of the Defendants, within 7 days of entry of this Order, must submit to the Commission an acknowledgment of receipt of this Order sworn under penalty of perjury.

B. For 20 years after entry of this Order, Defendant Huu Tieu, for any business that such Defendant, individually or collectively with any other Defendants, is the majority owner or controls directly or indirectly, and each Corporate Defendant, must deliver a copy of this Order to: (1) all principals, officers, directors, and LLC managers and members; (2) all employees having managerial responsibilities for conduct related to the subject matter of the Order and all agents and representatives who participate in conduct related to the subject matter of the Order; and (3) any business entity resulting from any change in structure as set forth in the Section titled Compliance Reporting. Delivery must occur within 7 days of entry of this Order for current personnel. For all others, delivery must occur before they assume their responsibilities.

C. From each individual or entity to which a Defendant delivered a copy of this Order, that Defendant must obtain, within 30 days, a signed and dated acknowledgment of receipt of this Order.

XII. COMPLIANCE REPORTING

IT IS FURTHER ORDERED that each of the Defendants make timely submissions to the Commission:

A. One year after entry of this Order, each Defendant must submit a compliance report, sworn under penalty of perjury:

1. Each of the Defendants must: (a) identify the primary physical, postal, and email address and telephone number, as designated points of contact, which representatives of the Commission may use to communicate with Defendant; (b) identify all of that Defendant's businesses by all of their names, telephone numbers, and physical, postal, email, and Internet addresses; (c) describe the activities of each business, including the goods and services offered, the means of advertising, marketing, and sales, and the involvement of any other Defendant (which Individual Defendants must describe if they know or should know due to their own involvement); (d) describe in detail whether and how that Defendant is in compliance with each Section of this Order; and (e) provide a copy of each Order Acknowledgment obtained pursuant to this Order, unless previously submitted to the Commission.
2. Additionally, Defendant Huu Tieu must: (a) identify all telephone numbers and all physical, postal, email and Internet addresses, including all residences; (b) identify all business activities, including any business for which such Defendant performs services whether as an employee or otherwise and any entity in which such Defendant has any ownership interest; and (c) describe in detail such

Defendant's involvement in each such business, including title, role, responsibilities, participation, authority, control, and any ownership.

B. For 20 years after entry of this Order, each Defendant must submit a compliance notice, sworn under penalty of perjury, within 14 days of any change in the following:

1. Each Defendant must report any change in: (a) any designated point of contact; or (b) the structure of any Corporate Defendant or any entity such that Defendant has any ownership interest in or controls directly or indirectly that may affect compliance obligations arising under this Order, including: creation, merger, sale, or dissolution of the entity or any subsidiary, parent, or affiliate that engages in any acts or practices subject to this Order.

2. Additionally, Defendant Huu Tieu must report any change in: (a) name, including aliases or fictitious name, or residence address; or (b) title or role in any business activity, including any business for which such Defendant performs services whether as an employee or otherwise and any entity in which such Defendant has any ownership interest, and identify the name, physical address, and any Internet address of the business or entity.

C. Each Defendant must submit to the Commission notice of the filing of any bankruptcy petition, insolvency proceeding, or similar proceeding by or against such Defendant within 14 days of its filing.

D. Any submission to the Commission required by this Order to be sworn under penalty of perjury must be true and accurate and comply with 28 U.S.C. § 1746, such as by concluding: "I declare under penalty of perjury under the laws of the United States of America

that the foregoing is true and correct. Executed on: _____" and supplying the date, signatory's full name, title (if applicable), and signature.

E. Unless otherwise directed by a Commission representative in writing, all submissions to the Commission pursuant to this Order must be emailed to DEbrief@ftc.gov or sent by overnight courier (not the U.S. Postal Service) to: Associate Director for Enforcement, Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW, Washington, DC 20580. The subject line must begin: *FTC v. Golden Sunrise Nutraceutical, Inc., et al.*, 1:20-cv-01060-DAD-SKO.

XV. RECORDKEEPING

IT IS FURTHER ORDERED that each of the Defendants must create certain records for 20 years after entry of the Order, and retain each such record for 5 years. Specifically, Corporate Defendants and Defendant Huu Tieu, for any business that such Defendant, individually or collectively with any other Defendants, is a majority owner or controls directly or indirectly, must create and retain the following records:

A. Accounting records showing the revenues from all goods or services sold;

B. Personnel records showing, for each person providing services, whether as an employee or otherwise, that person's: name; addresses; telephone numbers; job title or position; dates of service; and (if applicable) the reason for termination;

C. Records of all consumer complaints and refund requests, whether received directly or indirectly, such as through a third party, and any response;

D. All records necessary to demonstrate full compliance with each provision of this Order, including all submissions to the Commission; and

E. A copy of each unique advertisement or other marketing material.

XVI. COMPLIANCE MONITORING

IT IS FURTHER ORDERED that, for the purpose of monitoring each of the Defendants compliance with this Order, and any failure to transfer any assets as required by this Order:

A. Within 14 days of receipt of a written request from a representative of the Commission, each of the Defendants must: submit additional compliance reports or other requested information, which must be sworn under penalty of perjury; appear for depositions; and produce documents for inspection and copying. The Commission is also authorized to obtain discovery, without further leave of court, using any of the procedures prescribed by Federal Rules of Civil Procedure 29, 30 (including telephonic depositions), 31, 33, 34, 36, 45, and 69.

B. For matters concerning this Order, the Commission is authorized to communicate directly with each Defendant. The Defendants must permit representatives of the Commission to interview any employee or other person affiliated with any Defendant who has agreed to such an interview. The person interviewed may have counsel present.

C. The Commission may use all other lawful means, including posing, through its representatives as consumers, suppliers, or other individuals or entities, to Defendants or any individual or entity affiliated with Defendants, without the necessity of identification or prior notice. Nothing in this Order limits the Commission's lawful use of compulsory process, pursuant to Sections 9 and 20 of the FTC Act, 15 U.S.C. §§ 49 and 57b-1.

D. Upon written request from a representative of the Commission any consumer reporting agency must furnish consumer reports concerning Defendant Huu Tieu pursuant to Section 604(1) of the Fair Credit Reporting Act, 15 U.S.C. §1681b(a)(1).

XVII. RETENTION OF JURISDICTION

IT IS FURTHER ORDERED that this Court retains jurisdiction of this matter for purposes of construction, modification, and enforcement of this Order.

SO ORDERED this 17th day of October, 2025.

/s/ Daniel J. Calabretta
THE HONORABLE DANIEL J. CALABRETTA
UNITED STATES DISTRICT JUDGE

ATTACHMENT A

RE: About Your Treatment With Golden Sunrise Products

Dear [Name of Consumer]:

Our records show that you received the Emergency D-Virus Plan of Care, the Metabolic Plan of Care, or the Cancer Plan of Care.

The Federal Trade Commission (FTC), the nation's consumer protection agency, sued Golden Sunrise Nutraceutical, Inc., Golden Sunrise Pharmaceutical, Inc., Stephen Meis, M.D., and Huu Tieu for deceptively advertising certain products as effective ways to treat, cure, or lessen the symptoms of COVID-19, cancer, and Parkinson's disease.

Contrary to the advertising claims:

- There is no competent and reliable scientific proof that the Emergency D-Virus Plan of Care can treat, cure, or lessen the symptoms of COVID-19.
- There is no competent and reliable scientific proof that the Metabolic Plan of Care or Cancer Plan of Care can treat, cure, or lessen the symptoms of cancer.
- There is no competent and reliable scientific proof that the Metabolic Plan of Care can treat, cure, or lessen the symptoms of Parkinson's disease.
- None of the treatment plans were FDA approved, designated as Regenerative Medicine Advanced Therapies, or designated safe and effective by the FDA.

As part of a settlement with the FTC, I agreed to stop making these claims.

For more information about this lawsuit, visit https://www.ftc.gov/enforcement/cases-proceedings/202-3146/golden-sunrise-nutraceutical-inc. Learn how to spot and avoid false and unproven COVID-19 product claims at ftc.gov/coronavirus.

Sincerely,

Huu Tieu
Former President
Golden Sunrise Pharmaceutical, Inc.
Golden Sunrise Nutraceutical, Inc.

ATTACHMENT B

The envelope for the notification letter must be in the following form, with the underlined text completed as directed:

[Identify Respondent
Street Address
City, State, and Zip Code]

FORWARDING AND RETURN POSTAGE GUARANTEED ADDRESS CORRECTION SERVICE REQUESTED

[Name and
mailing address of customer,
including zip code]

ATTACHMENT C

[Date]
[Addressee]

RE: Removal of Misleading Health Treatment Claims Made by Golden Sunrise Nutraceutical, Golden Sunrise Pharmaceutical, Huu Tieu, and Stephen Meis

Dear Golden Sunrise Retailer:

The Federal Trade Commission (FTC), the nation's consumer protection agency, sued Golden Sunrise Nutraceutical, Inc., Golden Sunrise Pharmaceutical, Inc., Stephen Meis, M.D., and Huu Tieu for deceptively advertising certain products as effective ways to treat, cure, or lessen the symptoms of COVID-19, cancer, and Parkinson's disease.

To settle the charges, I have agreed to:

- Stop making claims that the Emergency D-Virus Plan of Care can treat, cure, or lessen the symptoms of COVID-19.
- Stop making claims that the Metabolic Plan of Care or Cancer Plan of Care can treat, cure, or lessen the symptoms of cancer.
- Stop making claims that the Metabolic Plan of Care can treat, cure, or lessen the symptoms of Parkinson's disease.
- Stop making claims that the plans of care were FDA approved, designated as Regenerative Medicine Advanced Therapies, or designated safe and effective by the FDA.

You should remove any point-of-sale displays, posters, or other materials on display that include any of the deceptive claims.

You can find out more about the settlement at https://www.ftc.gov/enforcement/cases-proceedings/202-3146/golden-sunrise-nutraceutical-inc. Please contact me if you have any questions at [contact information].

I thank you for your business and greatly appreciate your cooperation in this matter.

Sincerely,

Huu Tieu
Former President
Golden Sunrise Pharmaceutical, Inc.
Golden Sunrise Nutraceutical, Inc.